June 1-4, 2021 | Start Time TBD*
*Program is in development and subject to change
The live portion of this conference has concluded and all presentations are now available for purchase on demand. Registrants to the live event may access this content anytime for up to 9 months following the event.
Keystone Symposia welcomes the global scientific community and aims to connect researchers within and across disciplines to accelerate the advancement of biomedical and life sciences. This form may be used for scientists from low- and middle-income countries of all career stages to determine eligibility and request free access to scientific content presented during recent eSymposia events. If eligible, you will be sent an access code for the On Demand content of the eSymposia event(s) of interest.
Development of effective prophylactic human immunodeficiency virus (HIV) vaccines are still urgently needed to halt the spread of the HIV/AIDS pandemic. However, development of these vaccines has proven to be a challenge that, despite intensive research efforts over the last 30 years, science has failed to surmount. Nevertheless, the prospects for an effective HIV vaccine have recently been transformed by a series of advances in science. These advances suggest that induction of broadly-reactive antibodies that confer protection via neutralization and/or neutralization-independent mechanisms and elicitation of cytotoxic (CD8) T cell responses can potentially eradicate the virus early after transmission and may ultimately prove to be achievable goals for drug development.
This conference will bring together interdisciplinary investigators whose complementary expertise will synergize to inform HIV vaccine design and evaluation to discuss progress and outstanding challenges in areas such as: 1) The design of immunogens and strategies for optimization of germinal center responses to elicit HIV-1 broadly neutralizing antibodies; 2) Identifying prospects for harnessing other antibody effector functions to confer protection; 3) Developing approaches for eliciting rapidly-acting, efficacious HIV-specific CD8 T cell responses; and 4) How to use novel technologies, animal model systems and small-scale clinical trials to inform vaccine development efforts. This conference is being held jointly with HIV Pathogenesis and Cure. This pairing will provide an opportunity for interaction between investigators working in these related areas, and for joint discussion of therapeutic vaccination strategies.
Regular Registration Rate: $275 USD
Student Registration Rate: $150 USD
‣ For Short Talk Consideration: April 20, 2021
‣ For ePoster Presentation: May 18, 2021
Final ePoster / SciTalk Submission: May 21, 2021
Financial Aid Application: May 18, 2021
*Abstract submission is required in order to submit an ePoster and/or Scitalk
Graduate students and postdoctoral fellows, as well as individuals from low- and middle- income countries (all career stages) working in science and medicine-related fields, are eligible to apply for a FREE registration code.
Find out more about financial aid opportunities here!
Showcase your work to global audiences on the eSymposia platform!
Submit your abstract by the Short Talk Deadline for the opportunity to be selected for a short talk presentation alongside field leaders on the meeting program!
ePoster presenters will be provided with their own dedicated abstract listing on the event website to display their work in multiple formats, and interact with meeting participants. ePoster features include:
To submit your work for an ePoster presentation, and to be considered for short talk selection, go to the “Submit an Abstract” tab on the event homepage.
Walter Reed Army Institute of Research, USA
Dan H. Barouch
Beth Israel Deaconess Medical Center, USA
Michael R. Betts
University of Pennsylvania, USA
University of Oxford, UK
Barbara K. Felber
NCI, National Institutes of Health, USA
Guillaume J. Filion
Centre of Genomic Regulation, Spain
Weill Cornell Medicine, USA
Los Alamos National Laboratory, USA
M. Juliana McElrath
Fred Hutchinson Cancer Research Center, USA
Andrew J. McMichael
Oxford University, UK
IrsiCaixa AIDS Research Institute-HIVACAT, Spain
Institut Pasteur, France
Michel C. Nussenzweig
HHMI/Rockefeller University, USA
Rogier W. Sanders
University of Amsterdam and Weill Cornell Medical College, Netherlands
Kevin O. Saunders
Duke University, USA
Imperial College London, UK
U.S. Military HIV Research Program, USA
Georgia D. Tomaras
Duke University Medical Center, USA
US Military HIV Research Program, USA
Funding for this conference was made possible (in part) by Grant No. [GRANT NUMBER - UPDATE] from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.
This new virtual meeting format came out of difficult circumstances, but your commitment to scientific progress is what inspired us to launch Keystone eSymposia. In these virtual meetings, we are capturing the same innovative essence of our in-person meetings that you've all created as a scientific community. Here, Debbie Johnson, our CEO, explains how we're going to do that.